Wilsey Asset Management’s Biogen BIIB Stock Holding History

Wilsey Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100	Closed	-$1K	–	28
2021 Q1	$1K	Hold	100	–	–	﹤0.01%	24
2020 Q4	$3K	Buy	+100	New	+$25.8K	﹤0.01%	25

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wilsey Asset Management's BIIB Position: Q3 2021 in Review

Wilsey Asset Management sold out of Biogen (BIIB) in Q3 2021, closing a stake of 22,708 shares — an estimated $7.86M sold.

Wilsey Asset Management first reported a position in BIIB in Q4 2020 and held it in 3 quarters. The position peaked at $7.86M in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Wilsey Asset Management reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
Wilsey Asset Management sold 22,708 Biogen shares in Q3 2021, an estimated $7.86M.
Wilsey Asset Management first reported a position in Biogen in Q4 2020 and held it in 3 quarters.
Wilsey Asset Management's Biogen position peaked at $7.86M in Q2 2021.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Wilsey Asset Management's 13F filing for Q3 2021, filed 3 Nov 2021.